Al-Hassany Linda, van Drie Ruben W A, Boucherie Deirdre M, MaassenVanDenBrink Antoinette
Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, PO Box 2040, Rotterdam, 3000 CA, the Netherlands.
Division of Experimental Cardiology, Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Thoraxcenter, Rotterdam, 3000 CA, the Netherlands.
J Headache Pain. 2025 May 13;26(1):113. doi: 10.1186/s10194-025-02060-w.
We read with great interest the recent publication by Marston and colleagues in Nature Medicine, entitled "Endothelial cell-related genetic variants identify LDL cholesterol-sensitive individuals who derive greater benefit from aggressive lipid lowering" (issue 31, March 2025, pages 963-969). Among their compelling findings, the association between the endothelial cell-specific polygenic risk score (EC-PRS) - which consists of SNPs associated with coronary artery disease - and a reduced risk of migraine headaches stood out, although not being the study's primary aim. Migraine imposes a substantial individual and socioeconomic burden worldwide. Beyond its neurological manifestations as a primary headache disorder, migraine has increasingly been recognized as an independent and underappreciated cardiovascular risk factor, linked to major cardiovascular and cerebrovascular events. However, the biological underpinnings of this association remain poorly understood, particularly since they do not appear to be mediated through traditional or atherosclerotic pathways, and they are not associated with established cardiovascular risk factors. In this Correspondence, we build upon the findings of Marston et al. and contextualize them within the broader framework of migraine as a neurovascular disorder. Drawing from translational evidence, we propose a conceptual model that integrates findings regarding EC-PRS into the complex biological interplay linking migraine and cardiovascular disease, including coronary artery disease. In doing so, we aim to advance our understanding of migraine not only as a neurological disorder but as a marker of vascular vulnerability with implications for future research regarding personalized cardiovascular prevention, including statin therapy.
我们饶有兴趣地阅读了马斯顿及其同事近期发表在《自然·医学》上的文章,题为《内皮细胞相关基因变异可识别出对积极降脂获益更大的低密度脂蛋白胆固醇敏感个体》(2025年3月第31期,第963 - 969页)。在他们引人注目的研究结果中,由与冠状动脉疾病相关的单核苷酸多态性(SNP)组成的内皮细胞特异性多基因风险评分(EC - PRS)与偏头痛风险降低之间的关联尤为突出,尽管这并非该研究的主要目的。偏头痛在全球范围内给个人和社会经济带来了沉重负担。除了作为一种原发性头痛疾病的神经学表现外,偏头痛越来越被认为是一种独立且未得到充分认识的心血管危险因素,与主要的心血管和脑血管事件相关。然而,这种关联的生物学基础仍知之甚少,尤其是因为它们似乎并非通过传统或动脉粥样硬化途径介导,且与既定的心血管危险因素无关。在这篇通讯文章中,我们以马斯顿等人的研究结果为基础,并将其置于偏头痛作为一种神经血管疾病的更广泛框架中进行背景分析。借鉴转化医学证据,我们提出了一个概念模型,将关于EC - PRS的研究结果整合到连接偏头痛和心血管疾病(包括冠状动脉疾病)的复杂生物学相互作用中。这样做的目的是,我们不仅旨在加深对偏头痛作为一种神经系统疾病的理解,还旨在将其作为血管易损性的一个标志,为包括他汀类药物治疗在内的个性化心血管预防的未来研究提供启示。